Navigation Links
Adding epratuzumab to standard therapy
Date:5/16/2008

ROCHESTER, Minn. -- Adding a second monoclonal antibody drug to chemotherapy looks promising for treatment of diffuse large B-cell lymphoma, according to Mayo Clinic researchers working with the North Central Cancer Treatment Group (NCCTG) (http://ncctg.mayo.edu/). Results of this interim analysis were released May 15 as part of the 44th Annual Meeting of the American Society of Clinical Oncology.

Researchers found that 95 percent of patients responded to treatment that included the drug epratuzumab with the standard R-CHOP therapy. R-CHOP combines three chemotherapy drugs (cyclophosphamide, doxorubicin and vincristine) with the steroid drug prednisone and rituximab, a monoclonal antibody. Final results will be reported next year.

Diffuse large B-cell lymphoma is one of the most common and aggressive forms of non-Hodgkin lymphoma (NHL), a cancer of the white blood cells known as B-lymphocytes.

In 78 patients, researchers found:

  • 95 percent of participants (75 patients) improved as a result of the treatment.

  • 63 percent of participants (47 patients) were disease free.

Researchers also were able to look at the primary endpoint of the study -- disease-free survival at 12 months -- in 34 patients. Eighty five percent of that group, 29 patients, had no signs of lymphoma.

These results are good, but whether it will turn out to be better than standard therapy is still unknown, says the studys lead author, Ivana Micallef, M.D. (http://mayoresearch.mayo.edu/mayo/research/staff/micallef_in.cfm), a Mayo Clinic hematologist.

Epratuzumab is much like rituximab because both are monoclonal antibodies, and both attach to proteins commonly found on the surface of B-cells -- CD20 for rituximab and CD22 for epratuzumab. Both also are used to treat certain autoimmune disorders, such as rheumatoid arthritis and lupus. In autoimmune disease, you are trying to stop the B-cells from making the antibodies that cause inflammation, but in cancer, these B-cells are malignant, says Dr. Micallef.

This is the first large study to combine epratuzumab with chemotherapy, in this case R-CHOP.

The rate of toxic side effects among enrolled patients was the same as seen in R-CHOP use, investigators say. Overall, the combination was well tolerated, says Dr. Micallef. Patients may experience low blood counts, fatigue or infections.

As promising as these results look, researchers will not know if this new treatment provides superior results to R-CHOP unless the two regimens are compared with each other, she says.


'/>"/>

Contact: Traci Klein
newsbureau@mayo.edu
507-284-5005
Mayo Clinic
Source:Eurekalert

Related medicine news :

1. Coalition to Protect Floridas Drivers Applauds Governor Crist for Adding PIP to Special Session
2. Microsoft Dynamics CRM 4.0 Users now can include Telephony and Call Recording features by adding ConversationPRO(TM) from VoiceGate, a Division of IgeaCare Systems Inc.
3. Freeland, MI Woman Wins $50,000 for Losing Weight, Adding Muscle and Changing Her Life
4. Adding ultrasound screening to mammography brings benefits, risks
5. Majority of 2.4 Million U.S. Children With ADHD Not Diagnosed or Consistently Treated, According to New Gold Standard Study by Cincinnati Childrens Researchers
6. Standard Management Announces OTCBB Listing
7. Gastroenterology sets standards for CT colonography
8. Public Health and Need for Consistent Standards Preclude Exception for Breastfeeding Mother in National Medical Licensing Test
9. New Drug No Substitute for Standard Blood-Clot Therapy
10. National Quality Forum Issues First Consensus Standards for the Treatment of Substance Use Conditions
11. New guidelines set to improve standard of cows milk allergy care
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/1/2016)... Aliso Viejo, CA (PRWEB) , ... May 01, 2016 , ... ProBrand Reveal Volume 2 ... Pro X . With ProBrand Reveal Volume 2 keyframeless animations, users can easily create a ... over the look and feel of the various presets. Use these title presets to add ...
(Date:4/30/2016)... CA (PRWEB) , ... April 30, 2016 , ... ... on Dr. Carol Francis Talk Radio with Hypnotherapist, Mary O'Maley. What is ... help with habit control (substances, smoking, weight control), pain relief (chronic and acute), ...
(Date:4/30/2016)... Rosa, CA (PRWEB) , ... April 30, 2016 , ... “Aging well is a challenge for all of us, but ... NCMA’s Dr. Parul T. Kohli . “Research is showing more and more that there ... risk of disease and disability as we age.” Top priorities Dr. Kohli’s recommends for her patients ...
(Date:4/29/2016)... ... April 29, 2016 , ... Since ... the national charitable foundation serving the footwear industry, has broken all previous participation ... than 130 companies across 23 states during the months of April and May, ...
(Date:4/29/2016)... California (PRWEB) , ... April 29, 2016 , ... ... at the heart of our nation’s productivity, stability, even security. Most importantly, employees ... their organizations. , Then why are American workers so unhappy? , Just under ...
Breaking Medicine News(10 mins):
(Date:4/27/2016)... NORWALK, Conn. , April 27, 2016 /PRNewswire/ ... availability of its digital health technology platform, which ... services and programs into scalable digital products, Zillion ... mobile engagement and empower consumers to take control ... features face-to-face live video conferencing – including one-to-one, ...
(Date:4/27/2016)... , April 27, 2016  Bayer Animal ... a senior from the University of Florida College ... the Bayer Excellence in Communication Award (BECA). Brittany ... which were awarded a total of $70,000 in ... last four years, Bayer has provided a total ...
(Date:4/27/2016)... April 27, 2016 ... the  "Global Anesthesia Disposables Market 2016-2020"  report ... ) ,The global anesthesia disposables market ... of 4.03% during the period 2016-2020.  ... threat to patients, safety. Organizations like the ...
Breaking Medicine Technology: